Ovary
| TREATMENT REGIMENS | |||||
|---|---|---|---|---|---|
| First line treatment | |||||
| Carboplatin + paclitaxel (modified) | |||||
| Carboplatin AUC 6 + paclitaxel 80 DD | |||||
| IP Carboplatin + paclitaxel | |||||
| Niraparib maintenance | |||||
| Olaparib maintenance | |||||
| Second line treatment | |||||
| Platinum sensitive | |||||
| Carboplatin + paclitaxel (modified) | |||||
| Carboplatin + pegylated liposomal doxorubicin | |||||
| Niraparib | |||||
| Olaparib maintenance | |||||
| Platinum resistant | |||||
| Bevacizumab | |||||
| Pegylated liposomal doxorubicin | |||||
| Topotecan | |||||
| Germ cell tumors | |||||
Groupe d'étude en oncologie du Québec